Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-986435 (also known as MYK-224 and HCM-2) is an investigational small molecule drug developed for cardiovascular conditions. It acts as a cardiac myosin modulator and is being studied primarily for the treatment of heart failure with preserved ejection fraction (HFpEF) and hypertrophic cardiomyopathy. The drug aims to improve heart muscle function by modulating the activity of cardiac myosin, potentially offering a novel therapeutic approach distinct from existing treatments that do not target this pathway directly. Clinical trials are ongoing to evaluate its safety, tolerability, pharmacokinetics, and efficacy in both patients with HFpEF and those with symptomatic hypertrophic cardiomyopathy[1][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BMS-986435.